Literature DB >> 15700049

Suggestive linkage of schizophrenia to 5p13 in Costa Rica.

K Cooper-Casey1, A Mésen-Fainardi, B Galke-Rollins, M Llach, B Laprade, C Rodriguez, S Riondet, A Bertheau, W Byerley.   

Abstract

Schizophrenia afflicts roughly 1% of all people worldwide. Remarkably, despite differing cultures and environments, the expression of illness is essentially the same. Family, twin, and adoption studies identify schizophrenia as a genetically influenced disease. Linkage studies suggest many positive regions of interest, but as a complex genetic disorder most of the pathogenic loci have not yet been found. Isolated populations are commonly used to study rare Mendelian inherited diseases due to the more homogenous genetic background of the subjects and are thought to be useful for detecting linkage in complex genetic disorders such as schizophrenia. This study aims to define areas of the genome that exhibit co-inheritance with schizophrenia in one large, Mendelian-like family from the central valley of Costa Rica. The whole genome scan analysis of this pedigree, which included 11 cases of schizophrenia and schizoaffective disorder, identified a number of markers on chromosome 5p that appear to co-segregate with the disease with a maximum lod score of 2.70 at marker D5S426. Current studies include investigating additional Costa Rican pedigrees to replicate these findings and identify additional loci linked to the disease.

Entities:  

Mesh:

Year:  2005        PMID: 15700049     DOI: 10.1038/sj.mp.4001640

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  12 in total

1.  Genetic variations in the ADAMTS12 gene are associated with schizophrenia in Puerto Rican patients of Spanish descent.

Authors:  Irina N Bespalova; Gary W Angelo; Ben P Ritter; Jason Hunter; Maria L Reyes-Rabanillo; Larry J Siever; Jeremy M Silverman
Journal:  Neuromolecular Med       Date:  2012-02-10       Impact factor: 3.843

2.  Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population.

Authors:  Emily Moon; Brandi Rollins; Andrea Mesén; Adolfo Sequeira; Richard M Myers; Huda Akil; Stanley J Watson; Jack Barchas; Edward G Jones; Alan Schatzberg; William E Bunney; Lynn E DeLisi; William Byerley; Marquis P Vawter
Journal:  Schizophr Res       Date:  2011-07-13       Impact factor: 4.939

3.  Evidence of allelic imbalance in the schizophrenia susceptibility gene ZNF804A in human dorsolateral prefrontal cortex.

Authors:  Ilaria Guella; Adolfo Sequeira; Brandi Rollins; Ling Morgan; Richard M Myers; Stanley J Watson; Huda Akil; William E Bunney; Lynn E Delisi; William Byerley; Marquis P Vawter
Journal:  Schizophr Res       Date:  2013-12-07       Impact factor: 4.939

4.  Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample.

Authors:  Brian K Suarez; Jubao Duan; Alan R Sanders; Anthony L Hinrichs; Carol H Jin; Cuiping Hou; Nancy G Buccola; Nancy Hale; Ann N Weilbaecher; Deborah A Nertney; Ann Olincy; Susan Green; Arthur W Schaffer; Christopher J Smith; Dominique E Hannah; John P Rice; Nancy J Cox; Maria Martinez; Bryan J Mowry; Farooq Amin; Jeremy M Silverman; Donald W Black; William F Byerley; Raymond R Crowe; Robert Freedman; C Robert Cloninger; Douglas F Levinson; Pablo V Gejman
Journal:  Am J Hum Genet       Date:  2006-01-03       Impact factor: 11.025

5.  Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia.

Authors:  Daniel R Garton; Ana R Montaño-Rodríguez; Soophie Olfat; Kärt Mätlik; Feride Eren; Laoise Casserly; Anastasios Damdimopoulos; Anne Panhelainen; L Lauriina Porokuokka; Jaakko J Kopra; Giorgio Turconi; Nadine Schweizer; Erika Bereczki; Fredrik Piehl; Göran Engberg; Simon Cervenka; T Petteri Piepponen; Fu-Ping Zhang; Petra Sipilä; Johan Jakobsson; Carl M Sellgren; Sophie Erhardt; Jaan-Olle Andressoo
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 15.992

6.  Exome sequences of multiplex, multigenerational families reveal schizophrenia risk loci with potential implications for neurocognitive performance.

Authors:  Mark Z Kos; Melanie A Carless; Juan Peralta; Joanne E Curran; Ellen E Quillen; Marcio Almeida; August Blackburn; Lucy Blondell; David R Roalf; Michael F Pogue-Geile; Ruben C Gur; Harald H H Göring; Vishwajit L Nimgaonkar; Raquel E Gur; Laura Almasy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-09-13       Impact factor: 3.568

7.  Microarray comparative genomic hybridization analysis of 59 patients with schizophrenia.

Authors:  Takeshi Mizuguchi; Ryota Hashimoto; Masanari Itokawa; Akira Sano; Osamu Shimokawa; Yukiko Yoshimura; Naoki Harada; Noriko Miyake; Akira Nishimura; Hirotomo Saitsu; Nadiya Sosonkina; Norio Niikawa; Hiroshi Kunugi; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2008-08-07       Impact factor: 3.172

8.  Linkage analysis of schizophrenia in African-American families.

Authors:  H W Wiener; L Klei; M D Irvin; R T Perry; M H Aliyu; T B Allen; L D Bradford; M E Calkins; B Devlin; N Edwards; R E Gur; R C Gur; J Kwentus; P D Lyons; J P McEvoy; H A Nasrallah; V L Nimgaonkar; J O'Jile; A B Santos; R M Savage; R C P Go
Journal:  Schizophr Res       Date:  2009-03-05       Impact factor: 4.939

9.  Neuropsychological performance as endophenotypes in extended schizophrenia families from the Central Valley of Costa Rica.

Authors:  Hilary Bertisch; Andrea Mesen-Fainardi; Maureen V Martin; Vanessa Pérez-Vargas; Tatiana Vargas-Rodríguez; Gabriela Delgado; Camila Delgado; Michele Llach; Beatrice LaPrade; William Byerley; William E Bunney; Marquis P Vawter; Lynn E DeLisi
Journal:  Psychiatr Genet       Date:  2009-02       Impact factor: 2.458

10.  Meta-analysis of 32 genome-wide linkage studies of schizophrenia.

Authors:  M Y M Ng; D F Levinson; S V Faraone; B K Suarez; L E DeLisi; T Arinami; B Riley; T Paunio; A E Pulver; P A Holmans; M Escamilla; D B Wildenauer; N M Williams; C Laurent; B J Mowry; L M Brzustowicz; M Maziade; P Sklar; D L Garver; G R Abecasis; B Lerer; M D Fallin; H M D Gurling; P V Gejman; E Lindholm; H W Moises; W Byerley; E M Wijsman; P Forabosco; M T Tsuang; H-G Hwu; Y Okazaki; K S Kendler; B Wormley; A Fanous; D Walsh; F A O'Neill; L Peltonen; G Nestadt; V K Lasseter; K Y Liang; G M Papadimitriou; D G Dikeos; S G Schwab; M J Owen; M C O'Donovan; N Norton; E Hare; H Raventos; H Nicolini; M Albus; W Maier; V L Nimgaonkar; L Terenius; J Mallet; M Jay; S Godard; D Nertney; M Alexander; R R Crowe; J M Silverman; A S Bassett; M-A Roy; C Mérette; C N Pato; M T Pato; J Louw Roos; Y Kohn; D Amann-Zalcenstein; G Kalsi; A McQuillin; D Curtis; J Brynjolfson; T Sigmundsson; H Petursson; A R Sanders; J Duan; E Jazin; M Myles-Worsley; M Karayiorgou; C M Lewis
Journal:  Mol Psychiatry       Date:  2008-12-30       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.